Aluminium sucrose biscuit fillings to control hyperphosphataemia in patients undergoing dialysis.

نویسندگان

  • R Gabriel
  • J Morgan
چکیده

Aluminium hydroxide is used to prevent hyperphosphataemia in patients undergoing dialysis, but many standard preparations are unpalatable. In this study hydrated aluminium sucrose was suspended in synthetic cream and used as a biscuit filling. Six patients undergoing dialysis took part in five five-week study periods comparing different forms of treatment. No significant difference was found between serum phosphate concentrations measured during standard treatment and those measured during treatment with aluminium sucrose biscuits. There was no significant difference in serum phosphate concentrations when the patients were given placebo biscuits and when they received no treatment. Aluminium sucrose presented in this form was an adequate phosphate binder and was acceptable to the patients.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Determination of the serum level of aluminum & zinc in hemodialysis patients in Kerman,Iran

Dialysis is one of the effective methods which has been used since 1955 for the treatment of patients suffering from renal failure( more often of its chronic type). The dialysis results in the elimination of waste materials like urea and creatinine from the body, on the other hand, it can affect the serum contamination of the dialysis fluid. Aluminium is one of trace elements which its serum le...

متن کامل

Improving phosphate-binder therapy as a way forward.

Aluminium- or calcium-based phosphate-binding agents traditionally have been used to treat hyperphosphataemia in patients with end-stage renal disease. Although these agents effectively lower serum phosphorus levels, they are associated with serious side effects. Aluminium-based agents are associated with bone toxicity, renal osteodystrophy and encephalopathy, and calcium-based agents increase ...

متن کامل

Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.

More than 60% of patients on chronic haemodialysis (HD) have a serum phosphate level above 5.5 mg/dl (1.75 mmol/l), which recently has been recommended as an appropriate target in patients with end-stage renal disease (ESRD). Preventing hyperphosphataemia and elevated Ca x P product not only ameliorates the progression of secondary hyperparathyroidism and bone disease, but also appears to reduc...

متن کامل

Does aluminium have a pathogenic role in dialysis associated arthropathy?

Annals of the RHEUMATIC DISEASES Leader Does aluminium have a pathogenic role in dialysis associated arthropathy? Dialysis has improved the prognosis and quality of life for patients with chronic renal insufficiency, but at the price of various complications. The first to be recognised were the acute myoclonic encephalopathies,' 2 whose main cause is aluminium overload. This overload results fr...

متن کامل

Sevelamer does not have a distinct melting point. Differential Scanning Calorimetry

Treatment of hyperphosphataemia consists of dietary phosphorus restriction and/or dialysis and phosphate binders. Almost all dialysis patients require phosphate binders (calcium acetate, calcium carbonate, aluminium hydroxide). The use of calcium-based phosphate binders can result in chronic calcium overload, hypercalcemia and soft tissue calcification. Hypercalcemia is particularly common in p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • British medical journal

دوره 283 6286  شماره 

صفحات  -

تاریخ انتشار 1981